Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 15, 2020 | Published + Supplemental Material
Journal Article Open

Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalised Anxiety Disorder

Abstract

Background: Generalized anxiety disorder is associated with hyperactivity in the amygdala-prefrontal networks, and normalization of this aberrant function is thought to be critical for successful treatment. Preclinical evidence implicates cholinergic neurotransmission in the function of these systems and suggests that cholinergic modulation may have anxiolytic effects. However, the effects of cholinergic modulators on the function of anxiety-related networks in humans have not been investigated. Methods: We administered a novel α7 nicotinic acetylcholine receptor–negative allosteric modulator, BNC210, to 24 individuals (3 male subjects) with generalized anxiety disorder and assessed its effects on neural responses to fearful face stimuli. Results: BNC210 reduced amygdala reactivity to fearful faces relative to placebo and similarly to lorazepam and also reduced connectivity between the amygdala and the anterior cingulate cortex, a network involved in regulating anxious responses to aversive stimuli. Conclusions: These results demonstrate for the first time that the function of disorder-relevant neural circuits in generalized anxiety disorder can be beneficially altered through modulation of cholinergic neurotransmission and suggest potential for this system as a novel target for anxiolytic pharmacotherapy.

Additional Information

© 2020 Society of Biological Psychiatry. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Received 21 May 2019, Revised 25 November 2019, Accepted 11 December 2019, Available online 8 January 2020. The study was funded by Bionomics Ltd (to AHY and AMP). AHY, SCRW, and AMP are supported by the National Institute for Health Research Biomedical Research Centre at the South London and Maudsley National Health Service Foundation Trust and King's College London. This report represents independent research funded by the National Institute for Health Research Biomedical Research Centre and South London and Maudsley National Health Service Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, or Department of Health. TW is funded by a Wellcome Trust Sir Henry Wellcome fellowship. AHY and SCRW are members of the Bionomics Scientific Advisory Board. SMO and ED are employed by Bionomics Ltd. All other authors report no biomedical financial interests or potential conflicts of interest. EU Clinical Trials Register: A Randomized, Double-Blinded, Placebo and Lorazepam-Controlled, Four-Way Crossover, Phase II Study to Evaluate the Effects of Single Oral Administration of BNC210 on Brain Activity Changes Captured by Functional Magnetic Resonance Imaging in Adults With Generalized Anxiety Disorder; https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004937-15/GB; BNC210.006.

Attached Files

Published - 1-s2.0-S0006322319319377-main.pdf

Supplemental Material - 1-s2.0-S0006322319319377-mmc1.pdf

Supplemental Material - 1-s2.0-S0006322319319377-mmc2.xlsx

Files

1-s2.0-S0006322319319377-mmc1.pdf
Files (753.6 kB)
Name Size Download all
md5:e15e68429fec4629f0cce9f4628af737
20.7 kB Download
md5:86ea411372395e9bc1ce5052f1301cf3
123.6 kB Preview Download
md5:4e81c754eed0aa7257dd633f19139dbc
609.3 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 18, 2023